We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

Back to rankings

65 hedge funds and large institutions have $95.3M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

10% more funds holding

Funds holding: 59 → 65 (+6)

8% more capital invested

Capital invested by funds: $87.9M → $95.3M (+$7.39M)

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less call options, than puts

Call options by funds: $389K | Put options by funds: $451K

Holders
65
Holders Change
+6
Holders Change %
+10.17%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
18
Reduced
17
Closed
11
Calls
$389K
Puts
$451K
Net Calls
-$62K
Net Calls Change
-$463K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$5.66M
2
Morgan Stanley
Morgan Stanley
New York
+$4.47M
3
6CM
683 Capital Management
New York
+$1.19M
4
DA
DSC Advisors
Illinois
+$961K
5
JGC
J. Goldman & Co
New York
+$537K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$7.03M
2
SCM
Sio Capital Management
New York
-$2.8M
3
DAM
DLD Asset Management
New York
-$1.6M
4
BBA
Baker Bros. Advisors
New York
-$1.51M
5
Millennium Management
Millennium Management
New York
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
51
ProShare Advisors
Maryland
$44K -$10.4K -3,271 -20%
XM
52
XTX Markets
New York
$42K +$40.4K +12,702 New
DTL
53
Dynamic Technology Lab
Singapore
$35K +$33.2K +10,440 New
PAG
54
Private Advisor Group
New Jersey
$33K – – –
PAPAIJV
55
Paragon Associates & Paragon Associates II Joint Venture
Texas
$33K +$31.8K +10,000 New
Citigroup
56
Citigroup
New York
$16K +$10K +3,146 +196%
Victory Capital Management
57
Victory Capital Management
Texas
$14K – – –
AA
58
AlphaMark Advisors
Kentucky
$10K +$3.94K +1,240 +69%
ASN
59
Advisory Services Network
Georgia
$10K +$10K +3,150 New
UBS Group
60
UBS Group
Switzerland
$8K -$28.1K -8,826 -78%
LTFS
61
Ladenburg Thalmann Financial Services
Florida
$3K +$318 +100 +10%
TWA
62
TCI Wealth Advisors
Arizona
$3K +$2.54K +800 New
CCM
63
Cribstone Capital Management
Maine
$1K – – –
Daiwa Securities Group
64
Daiwa Securities Group
Japan
$1K – – –
SCM
65
Sio Capital Management
New York
– -$2.8M -920,796 Closed
DAM
66
DLD Asset Management
New York
– -$1.6M -525,000 Closed
BBA
67
Baker Bros. Advisors
New York
– -$1.51M -498,189 Closed
Millennium Management
68
Millennium Management
New York
– -$1.05M -345,100 Closed
DCM
69
DAFNA Capital Management
California
– -$929K -305,500 Closed
SSA
70
Schonfeld Strategic Advisors
New York
– -$530K -174,500 Closed
OAM
71
Oxford Asset Management
United Kingdom
– -$216K -71,069 Closed
Renaissance Technologies
72
Renaissance Technologies
New York
– -$186K -61,119 Closed
WVP
73
Worth Venture Partners
New Jersey
– -$72K -23,627 Closed
Citadel Advisors
74
Citadel Advisors
Florida
– -$45K -14,753 Closed
Deutsche Bank
75
Deutsche Bank
Germany
– -$33K -10,898 Closed
1 2
3
4

FOMX Hedge Fund Activity: Q4 2019 in Review

65 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2019, worth a combined $95.3M — up 8.4% from $87.9M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FOMX positions and 11 closed out — a net gain of 6 holders — while 18 added to existing stakes and 17 trimmed.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $5.66M. The largest seller was OrbiMed, cutting an estimated $7.03M.

  • 65 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2019, up from 59 in Q3 2019.
  • Funds reported $95.3M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2019, up 8.4% quarter-over-quarter.
  • 17 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2019 and 11 closed out, a net change of +6 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2019 was Mangrove Partners, an estimated $5.66M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2019 was OrbiMed, an estimated $7.03M sold.

Based on aggregated 13F filings for Q4 2019.